| CAS NO: | 85409-38-7 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 278.24 |
|---|---|
| Formula | C10H19N2O5P |
| CAS No. | 85409-38-7 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 55 mg/mL (197.67 mM) |
| Water: <1 mg/mL | |
| Ethanol: 1 mg/mL warmed (3.59 mM) | |
| SMILES | C1CC1C(C2CC2)NC3=NCCO3.OP(=O)(O)O |
| Synonyms | S 3341; S3341; S-3341 |
| In Vitro | In vitro activity: Rilmenidine phosphate is the water soluble form of Rilmenidine. It is an antihypertensive drug targets the imidazoline receptor. Cell Assay: In Hep G2 cells treated with 0.5 mM oleic acid for 6 hours and 1μm Rilmenidine for 30 minutes, the oleic acid-induced lipid accumulation decreases. Stimulation of imidazoline I-1 receptor by Rilmenidine activated P38 to induce the expression of FXR. |
|---|---|
| In Vivo | Mice fed with HFD (high fat diet) had improved hepatic steatosis following the administration of Rilmenidien through the activation of imidazoline I-1 receptor. Imidazoline receptors are involved in the bulbospinal regulation of blood pressure and affect peripheral stimulation. In hypertensive patients, Rilmenidine decreased blood pressure in a dose-dependent mater. In contrast with placebo, Rilmenidine had significantly lowered blood pressures. In addition, Rilmenidine had significantly less incidences of adverse effects than using other drugs for hypertension. |
| Animal model | |
| Formulation & Dosage | |
| References | Am J Hypertens. 1992 Apr;5(4 Pt 2):99S-105S; Annu Rev Pharmacol Toxicol. 1996;36:511-44; Cardiovasc Hematol Agents Med Chem. 2006 Jan;4(1):17-32; Naunyn Schmiedebergs Arch Pharmacol. 2012 Jan;385(1):51-6. |
m.cnreagent.com